Inclusion Criteria:  Have signed the informed consent form; Participants of both genders aged ≥ 18 years; Essential hypertension based on a Diastolic Blood Pressure (DBP) > 90 mmHg and < 110 mmHg; Patients with no treatment or on antihypertensive therapy taking up to two anti-hypertensives; Possibility of discontinuing previous antihypertensive medication during the washout period.  Exclusion Criteria:  Essential hypertension based on a Diastolic Blood Pressure (DBP) ≥ 110mmHg and Systolic Blood Pressure (SBP) ≥ 180 mmHg; Secondary hypertension; Participants with Body Mass Index (BMI) > 35 Kg/m2; Non-controlled types 1 and 2 diabetes mellitus (HbA1 > 8,5%); Myocardial infarction, coronary surgery or coronary angioplasty with or without stent placement, in the last 6 months; Unstable angina; Participants with coronary heart disease taking beta-blockers; Clinically manifest heart failure; History of cardiac arrhythmia; Moderate and severe heart valve disease; Stroke or transient ischemic attack in the last 6 months; Chronic disease of any nature that contraindicates the participant's participation according to the investigator's judgment, in particular renal failure with glomerular filtration rate < 45 ml/min, serum potassium levels ≥ 5,5 mEq/L or ≤ 3,5 mEq/L, hepatopathies, or SGOT, SGPT or bilirubin levels 3 times above the normal upper limit, and blood dyscrasias; Known allergies or contraindication to the use of the study medication components; Female participants who are pregnant, breastfeeding or who want to become pregnant; COVID-19 symptoms; Post COVID-19 syndrome with cardiovascular impairment; Subjects who have participated in other study within the 12 months prior to screening (unless benefit is justified by the researcher).